<span item_type="fundamental" item_id="218d4569e5c781dc485fb781f03d14be" counter_id="ST/US/BACK" env="prod"></span><span item_type="announcement" item_id="594768969041714945" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 21.22 K.</p><p>EPS: As of FY2025 Q3, the actual value is USD -1.15.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -2.135 M.</p><p></p><h3>Segment Revenue</h3><ul><li>For the three months ended September 30, 2025, IMAC Holdings, Inc. reported net revenue of $0.02 million, compared to $0.06 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1729944/000149315225028190/form10-q.htm"></span></li><li>For the nine months ended September 30, 2025, net revenue was $0.02 million, compared to $0.07 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1729944/000149315225028190/form10-q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>The company reported a net loss of $3.1 million for the three months ended September 30, 2025, compared to a net loss of $2.2 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1729944/000149315225028190/form10-q.htm"></span></li><li>For the nine months ended September 30, 2025, the net loss was $7.4 million, compared to $4.0 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1729944/000149315225028190/form10-q.htm"></span></li><li>Operating expenses for the three months ended September 30, 2025, were $2.5 million, up from $1.9 million in the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1729944/000149315225028190/form10-q.htm"></span></li><li>Operating expenses for the nine months ended September 30, 2025, were $6.4 million, compared to $3.7 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1729944/000149315225028190/form10-q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Net cash used in operating activities for the nine months ended September 30, 2025, was $3.8 million, compared to $2.0 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1729944/000149315225028190/form10-q.htm"></span></li><li>Net cash provided by financing activities during the nine months ended September 30, 2025, was $3.3 million, primarily from the sale of common stock and issuance of promissory notes.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1729944/000149315225028190/form10-q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>The company recognized an impairment loss of $0.75 million on laboratory equipment during the three months ended September 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1729944/000149315225028190/form10-q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: IMAC Holdings, Inc. plans to focus on its precision medicine in cancer treatment, leveraging its RPPA technology platform to support oncology clinical treatment decisions and biopharmaceutical drug development.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1729944/000149315225028190/form10-q.htm"></span></li><li><strong>Non-Core Business</strong>: The company has discontinued operations related to patient care at all locations as of December 31, 2023, and is focusing on its laboratory capabilities acquired from Theralink Technologies, Inc.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1729944/000149315225028190/form10-q.htm"></span></li><li><strong>Priority</strong>: The company aims to raise additional capital to fund future operations and mitigate substantial doubt about its ability to continue as a going concern.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1729944/000149315225028190/form10-q.htm"></span></li></ul>

Imac | 10-Q: FY2025 Q3 Revenue: USD 21.22 K